Vericel Corporation, a commercial-stage biopharmaceutical company, researches, develops, manufactures, markets, and sells patient-specific expanded cellular therapies to repair and regenerate damaged tissues and organs. It markets autologous cell therapy products, including MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Carticel, an autologous chondrocyte implant for the repair of symptomatic cartilage defects of the femoral condyle caused by acute or repetitive trauma in patients that have inadequate response to a prior arthroscopic or other surgical repair procedure. The company also markets Epicel, a permanent skin replacement humanitarian use device for the treatment of patients with deep-dermal or full-thickness burns. In addition, it develops ixmyelocel-T, a patient-specific multicellular therapy that has completed Phase IIb clinical trial for the treatment of advanced heart failure due to ischemic dilated cardiomyopathy. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was founded in 1989 and is headquartered in Cambridge, Massachusetts.
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone800-556-0311
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$63.92 million
Profitability
Miscellaneous
Employees205
OptionableOptionable
Vericel (NASDAQ:VCEL) Frequently Asked Questions
What is Vericel's stock symbol?
Vericel trades on the NASDAQ under the ticker symbol "VCEL."
How were Vericel's earnings last quarter?
Vericel Corp (NASDAQ:VCEL) announced its earnings results on Monday, August, 6th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.12). The biotechnology company earned $19.01 million during the quarter, compared to analyst estimates of $18.51 million. Vericel had a negative return on equity of 17.39% and a negative net margin of 15.80%. View Vericel's Earnings History.
When is Vericel's next earnings date?
What price target have analysts set for VCEL?
6 equities research analysts have issued twelve-month target prices for Vericel's stock. Their forecasts range from $14.00 to $23.00. On average, they anticipate Vericel's share price to reach $18.00 in the next twelve months. This suggests that the stock has a possible downside of 7.6%. View Analyst Price Targets for Vericel.
What is the consensus analysts' recommendation for Vericel?
6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Vericel in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Vericel.
Has Vericel been receiving favorable news coverage?
Media coverage about VCEL stock has trended negative on Sunday, InfoTrie Sentiment Analysis reports. InfoTrie identifies negative and positive news coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Vericel earned a news sentiment score of -2.8 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next several days.
Who are some of Vericel's key competitors?
Some companies that are related to Vericel include China Biologic Products (CBPO), Repligen (RGEN), Halozyme Therapeutics (HALO), Spark Therapeutics (ONCE), Denali Therapeutics (DNLI), Acceleron Pharma (XLRN), Aerie Pharmaceuticals (AERI), Atara Biotherapeutics (ATRA), Regenxbio (RGNX), Crispr Therapeutics (CRSP), Alector (ALEC), Momenta Pharmaceuticals (MNTA), Orchard Therapeutics (ORTX), Iovance Biotherapeutics (IOVA) and Autolus Therapeutics (AUTL).
Who are Vericel's key executives?
Vericel's management team includes the folowing people:
- Mr. Dominick C. Colangelo, CEO, Pres & Director (Age 55)
- Mr. Gerard J. Michel, CFO & VP of Corp. Devel. (Age 56)
- Mr. Daniel R. Orlando, Chief Operating Officer (Age 54)
- Ms. Jacquelyn Fahey Sandell, VP, Gen. Counsel & Corp. Sec.
- Ms. Heidi Hassen, Sr. Director of HR
Who are Vericel's major shareholders?
Vericel's stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (6.84%), RTW Investments LP (5.28%), Northern Trust Corp (1.27%), First Washington CORP (1.17%), Geode Capital Management LLC (1.15%) and Castleark Management LLC (0.93%). Company insiders that own Vericel stock include Alan L Rubino, Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Institutional Ownership Trends for Vericel.
Which institutional investors are selling Vericel stock?
VCEL stock was sold by a variety of institutional investors in the last quarter, including Acadian Asset Management LLC, Two Sigma Investments LP, First Washington CORP, Millennium Management LLC, PNC Financial Services Group Inc., Timpani Capital Management LLC, Chartwell Investment Partners LLC and D. E. Shaw & Co. Inc.. Company insiders that have sold Vericel company stock in the last year include Daniel Orlando, Dominick Colangelo, Gerard J Michel, Paul K Wotton and Steven C Gilman. View Insider Buying and Selling for Vericel.
Which institutional investors are buying Vericel stock?
VCEL stock was acquired by a variety of institutional investors in the last quarter, including Oberweis Asset Management Inc., Public Employees Retirement System of Ohio, Bank of New York Mellon Corp, BlackRock Inc., RTW Investments LP, Broadfin Capital LLC, GSA Capital Partners LLP and 361 Capital LLC. View Insider Buying and Selling for Vericel.
How do I buy shares of Vericel?
Shares of VCEL can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Vericel's stock price today?
One share of VCEL stock can currently be purchased for approximately $19.49.
How big of a company is Vericel?
Vericel has a market capitalization of $844.83 million and generates $63.92 million in revenue each year. The biotechnology company earns $-17,280,000.00 in net income (profit) each year or ($0.50) on an earnings per share basis. Vericel employs 205 workers across the globe.
What is Vericel's official website?
How can I contact Vericel?
Vericel's mailing address is 64 SIDNEY STREET, CAMBRIDGE MA, 02139. The biotechnology company can be reached via phone at 800-556-0311 or via email at [email protected]
MarketBeat Community Rating for Vericel (NASDAQ VCEL)
MarketBeat's community ratings are surveys of what our community members think about Vericel and other stocks. Vote "Outperform" if you believe VCEL will outperform the S&P 500 over the long term. Vote "Underperform" if you believe VCEL will underperform the S&P 500 over the long term. You may vote once every thirty days.
